Symposium 1 – Open (in partnership with American Society for Clinical Investigation (ASCI))
The American Society for Clinical Investigation seeks to support the scientific efforts, educational needs, and clinical aspirations of physician-scientists to improve the health of all people. The ASCI comprises more than 3,000 physician-scientists from all medical specialties representing the rich diversity of backgrounds inherent to those they serve. The ASCI is dedicated to the advancement of research that extends our understanding and improves the treatment of diseases of all people, and members are committed to mentoring future generations of physician-scientists of diverse backgrounds and biomedical disciplines. Founded in 1908, the ASCI is one of the oldest and most respected nonprofit medical honor societies in the United States and is a key organization focused on the special role of physician-scientists in research, clinical care, and medical education, in addition to leadership roles many members hold in academic medicine and the life-sciences industry. Membership is gained through nomination and election — a milestone in the physician-scientist career path. The ASCI holds its members to the highest standards of integrity, professionalism, mutual respect, and collegiality — fostering a culture of trust and inclusivity.
Symposium 2 – Genomics (in partnership with British Pharmacological Society)
The British Pharmacological Society is a charity with a mission to promote and advance the whole spectrum of pharmacology. Founded in 1931, it is now a global community at the heart of pharmacology, with around 5,000 members from more than 60 countries worldwide. The Society leads the way in the research and application of pharmacology around the world through its scientific meetings, educational resources and peer-reviewed journals.
Symposium 3 – Infectious Diseases (in partnership with Science Translational Medicine)
Science Translational Medicine is the leading weekly online journal publishing translational research at the intersection of science, engineering and medicine. The goal of Science Translational Medicine is to promote human health by providing a forum for communicating the latest research advances from biomedical, translational, and clinical researchers from all established and emerging disciplines relevant to medicine. Despite 50 years of progress in our fundamental understanding of human biology and the emergence of powerful new technologies, the translation of this knowledge into effective new treatments and health measures has been slow. Science Translational Medicine seeks to publish articles that fill the scientific knowledge gaps at the junction of preclinical research and medical applications in order to accelerate the translation of this knowledge into new ways for preventing, diagnosing and treating human disease.
Symposium 4 – Data Science (in partnership with Clinical Science)
Science Translational Medicine is the leading weekly online journal publishing translational research at the intersection of science, engineering and medicine. The goal of Science Translational Medicine is to promote human health by providing a forum for communicating the latest research advances from biomedical, translational, and clinical researchers from all established and emerging disciplines relevant to medicine. Despite 50 years of progress in our fundamental understanding of human biology and the emergence of powerful new technologies, the translation of this knowledge into effective new treatments and health measures has been slow. Science Translational Medicine seeks to publish articles that fill the scientific knowledge gaps at the junction of preclinical research and medical applications in order to accelerate the translation of this knowledge into new ways for preventing, diagnosing and treating human disease.
Founded in 1911, the Biochemical Society has been at the forefront of advancing molecular bioscience for over 100 years, promoting its importance as a discipline, facilitating the sharing of knowledge and expertise, and supporting molecular bioscientists across all career stages. Working in partnership with researchers, institutions, and funders, we publish world-leading research and reviews across a portfolio of seven journals via our publishing arm, returning all profits to the life science community in support of our charitable activities. With more than 5.4 million worldwide article views in 2022, our journals cover the breadth of the molecular biosciences and support the transition to a more open scholarly landscape.
Clinical Science, a Biochemical Society journal, is a peer-reviewed hybrid journal offering the option to publish open access. Translating molecular bioscience and experimental research into medical insights, papers published in Clinical Science cover a range of topics, including the cardiovascular system and vascular biology, genomic medicine, inflammation, nephrology, hepatology, cancer biology, and the respiratory system. The journal’s breadth of coverage within the life sciences attracts a strong research community, supporting our key journal mission of linking basic science to disease mechanisms.
Symposium 5 – Neurological Diseases (in partnership with The Lancet)
About The Lancet Group | The best science for better lives
The Lancet began as an independent, international weekly general medical journal founded in 1823 by Thomas Wakley. Since its first issue (Oct 5, 1823), the journal has strived to make science widely available so that medicine can serve and transform society, and positively impact the lives of people. Over the past two centuries, The Lancet has sought to address urgent topics in our society, initiate debate, put science into context, and influence decision makers around the world. The Lancet has evolved as a family of journals and other services, which retain and reflect our core belief that medicine must serve society, that knowledge must transform society, that the best science must lead to better lives. Visit www.thelancet.com/about-us to learn more about The Lancet Group.
